U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159204) titled 'Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer' on Aug. 20.
Brief Summary: After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen
Study Start Date: Jan. 01, 2023
Study Type: INTERVENTIONAL
Condition:
Biliary Tract Cancer (BTC)
Intervention:
DRUG: Paclitaxel polymer micelle immunocombination
Paclitaxel polymer micelle immunocombination
Recruitment Status: RECRUITING
Sponsor: Peking Union Medical College Hospital
Published by HT Digital Content Services with permission from Health Daily Digest....